Evofem, the startup trying to survive the broken birth-control market, finally sells itself
Aditxt is buying the buzzy but controversial maker of Phexxi, in a deal valued at $100 million.
Fortune ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
UNCOVERED: Phexxi - The Untold Story
Birth control fail: Why American women can’t have better contraceptives in 2023
The rocky history of Evofem and Phexxi illuminates how big insurers and drugmakers are stifling innovation in women’s health.
Fortune ·
Evofem Shares Jump On Interim Q4 Sales, Phexxi Prescriptions
Evofem Biosciences Inc (NASDAQ: EVFM) achieved preliminary net
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Fortune
Benzinga
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
